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Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease characterized by 
excessive inflammation and disrupted skin barrier function. Although the etiology of AD 
is not completely understood, clinical and basic studies suggest increasing involvement 
of autoantibodies against intracellular proteins. An actin remodeling protein, Flightless I 
(Flii), has been shown to promote development of inflammatory mediated skin conditions 
and impairment of skin barrier development and function. Here, we sought to determine 
the effect of altering Flii expression on the development of AD and its contribution to 
autoimmune aspects of inflammatory skin conditions. Ovalbumin (OVA)-induced AD 
skin-like disease was induced in Flii heterozygous (Flii+/−), wild-type (Flii+/+), and Flii 
transgenic (FliiTg/Tg) mice by epicutaneous exposure to OVA for 3  weeks; each week 
was separated by 2-week resting period. Reduced Flii expression resulted in decreased 
disease severity and tissue inflammation as determined by histology, lymphocytic, and 
mast cell infiltrate and increased anti-inflammatory IL-10 cytokine levels and a marked 
IFN-γ Th1 response. In contrast, Flii over-expression lead to a Th2 skewed response 
characterized by increased pro-inflammatory TNF-α cytokine production, Th2 chemokine 
levels, and Th2 cell numbers. Sera from OVA-induced AD skin-like disease Flii+/− mice 
showed a decreased level of autoreactivity while sera from FliiTg/Tg mice counterparts 
showed an altered autoantibody profile with strong nuclear localization favoring devel-
opment of a more severe disease. These findings demonstrate autoimmune responses 
in this model of OVA-induced AD-like skin disease and suggest that Flii is a novel target, 
whose manipulation could be a potential approach for the treatment of patients with AD.
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inTrODUcTiOn
Atopic dermatitis (AD) is one of the most common heterogeneous inflammatory skin diseases 
affecting 20% of children and 1–3% of adults worldwide (1). The disease is associated with impair-
ments in the skin barrier and variable clinical indicators including occurrence of eczematous lesions, 
pruritus, and cheilitis (1). The etiology of AD is complex and is often characterized by abnormal 
immunological pathways that manifest in an imbalance of T-helper (Th)1 and Th2 responses (2). 
Typically, AD is described as having a biphasic course consisting of an acute inflammatory Th2-
dominated phase associated with IgE production and a chronic phase distinguished by reappearance 
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of Th1 responses, tissue remodeling, and dermal thickening (3). 
Histopathologically, AD is characterized by an inflammatory 
infiltrate consisting of CD4+ memory T cells, mast cells, and 
eosinophils and a controlled temporal-spatial expression of pro-
inflammatory cytokines and chemokines driving atopic inflam-
mation of the skin (4).
Research within the last decade has found an association 
between AD and autoantibody development, suggesting the contri-
bution of autoantibodies to the pathogenesis of AD (3, 5–8). It is 
proposed that tissue damage induced by AD allows exposure of 
intracellular antigens that are normally inaccessible by antibodies 
to the extracellular space, where they can interact with B cells and 
antibodies (9). A broad spectrum of IgE targeting self-antigens 
have been identified in above 90% of severe AD patients and 
high-avidity IgG autoantibodies have been proposed as potential 
diagnostic markers for severe AD (5, 10–12). The fact that these 
autoantibodies are associated with disease severity implicates 
their role in both humoral and cellular immunity in AD patho-
genesis (5, 12). Antinuclear antibodies have been shown to have 
both biological and clinical significance acting as sensors of 
cellular stress and inflammation associated with environmental 
factors (13). While the presence of autoantibodies can have a 
protective role as natural autoantibodies (14), the presence of 
nuclear autoantibodies in AD has been suggested to lead to the 
continual provocation of the immune system hence contributing 
to the severity and chronicity of disease.
Flightless I (Flii) is a highly conserved and unique member 
of the gelsolin family of actin remodeling proteins and a nuclear 
receptor activator affecting the transcriptional activity of many 
modulators of tissue remodeling and inflammation (15, 16). Flii 
has been demonstrated to regulate cytokine secretion and cellular 
inflammatory responses via its intracellular and extracellular 
effects on toll-like receptors (17–20). Flii expression increases 
in skin during development and in response to inflammation, 
injury, skin cancer development, wound healing, and skin blis-
tering (21–23). Over-expression of Flii delays the development 
of an intact skin barrier in the embryonic skin of mice and impairs 
the recovery of the epidermal barrier post injury via its effects 
on tight-junction formation (22). A recent study has shown that 
reducing Flii levels either genetically or using Flii neutralizing 
antibodies decreases erythema, inflammatory cell infiltrate, and 
pro-inflammatory cytokine secretion in a mouse model of pso-
riasiform dermatitis (24). Taken together, these findings suggest 
a possible role for Flii in inflammatory responses mediating AD. 
Using an OVA-induced AD-like skin mouse model (25), this study 
aimed to investigate the effect of differential Flii gene expression 
on development of AD via characterization of inflammatory and 
autoimmune responses responsible for AD pathogenesis.
MaTerials anD MeThODs
animal studies
Mice were maintained according to the Australian Code for the 
Care and Use of Animals for Scientific Purposes under protocols 
approved by the Child Youth and Women’s Health Service Animal 
Ethics Committee (AEC916/06/2015). Mice with the BALB/c 
background and wild-type controls were obtained from inbred 
litters. Flii-deficient heterozygous null mice (Flii+/−) and mice 
carrying the complete human Flii gene on a cosmid transgene 
were maintained as described previously (26, 27). Heterozygous 
transgenic mice FliiTg/+ were made by crossing Flii+/+ with cosmid 
transgene Flii+/−. These transgenic mice were intercrossed to 
obtain animals homozygous for the transgene FliiTg/Tg which carry 
two copies of the mouse Flii gene and two copies of the human 
Flii transgene.
Atopic dermatitis was induced via epicutaneous exposure of 
mice to OVA as previously described (25). Briefly, 10- to 12-week-
old female wild-type (Flii+/+), Flii heterozygous (Flii+/−), and Flii 
transgenic (FliiTg/Tg) mice (n = 8/genotype) were anesthetized 
using isoflurane inhalation, the skin on the back of mice was 
shaved and then tape stripped four times by a transparent adhe-
sive tape (Tegaderm) to introduce a standardized skin injury. 
A gauze patch (1 × 1 cm2) soaked with 100 µl of 0.1% OVA (OVA 
group) in saline or 0.9% saline (control group) was placed on the 
back skin and secured with Tegaderm dressing. The experiment 
comprised three 1-week exposures with a 2-week interval between 
each exposure week (Figure 1A). Clinical images of affected skin, 
transepidermal water loss (TEWL), and erythema measurements 
were recorded at the end of the third sensitization week. The level of 
skin erythema was measured daily using a handheld DermaLab 
Unit (Cortex Technology) following manufacturer’s instructions. 
This instrument uses skin reflectance spectroscopy to determine 
the redness of inflamed skin. The instrument was blanked prior 
to placing a probe directly onto the inflamed AD-like lesions 
on dorsal skin and a reading obtained as previously described 
(24). Measurements of TEWL were obtained with a calibrated 
Vapometer evaporimeter (Delfin Technologies, Finland). The 
probe was allowed to equilibrate for approximately 30  s before 
a brief measurement period (8 s) as indicated in manufacturer’s 
guidelines. The Vapometer was placed directly onto the inflamed 
AD-like lesions on dorsal skin (using an 11-mm adaptor) and 
held there securely for the duration of the measurement. For both 
erythema and TEWL analysis, three separate measurements were 
taken per mouse to ensure the entire region of AD-like inflamed 
back skin was assessed as previously described (24). Mice were 
then euthanized and skin biopsies collected for histology analysis, 
immunohistochemistry, and mRNA extraction. Blood was col-
lected for autoimmunity experiments.
histology and immunohistochemistry
Paraffin-embedded fixed tissue samples were stained with 
hema toxylin and eosin or toluidine blue following established 
proto cols (28). Level of skin inflammation was assessed using 
skin thickness measurements, and analysis of inflammatory and 
mast cell numbers in lesional skin of OVA-induced AD-like skin 
lesions of Flii+/−, wild-type, and FliiTg/Tg mice using high magni-
fication images and light microscopy using optimized protocols 
using Image Pro-Plus 5.1 program (MediaCybernetics Inc.) as 
previously described (24). Skin thickness included epidermal and 
dermal measurements of OVA-induced AD-like lesions; inflam-
matory cell number was assessed by counting total inflammatory 
cells in 10 different HPF of view in OVA-induced AD-like lesions, 
and mast cell analysis included counting toludine blue positive 
FigUre 1 | Reduced Flii expression leads to decreased development of OVA-induced atopic dermatitis (AD)-like lesions. (a) Ovalbumin (OVA) exposure  
protocol, including a total of three 1-week exposures to 100 µl 0.1% OVA or saline control on patches separated from each other by 2-week resting interval.  
(B) Representative clinical images of OVA-induced AD-like skin lesions in mice differential Flii expression illustrating high degree of erythema, skin thickening,  
and scaling (black arrowhead) in WT and FliiTg/Tg mice exposed to OVA. (c,D) OVA exposure leads to development of AD-like lesions demonstrated by increased 
erythema and transepidermal water loss (TEWL). Decreasing Flii expression reduces development of AD-like lesions with significantly decreased erythema and 
TEWL measurements compared to OVA exposed skin of WT and FliiTg/Tg animals. n = 8. Mean ± SEM. *<0.05.
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mast cells in entire sections of OVA-induced AD-like skin lesions 
per mm2. Immunohistochemistry was also performed on paraffin-
embedded fixed AD-like skin lesions following antigen retrieval 
according to the manufacturer’s protocols (DAKO Corporation, 
Glostrup, Denmark). Following blocking in 3% normal goat 
serum, primary antibodies against CD4 [rat monoclonal, #14-
9766-82 (Thermo Scientific, Australia) (1:200)], T-bet [rabbit 
polyclonal, #PA5-40573 (Thermo Scientific, Australia) (1:100)], 
GATA-3 [rabbit polyclonal, #ab106625 (Abcam Australia) 
(1:100)], and ROR-γ [rabbit monoclonal, #ab207082 (Abcam 
Australia) (1:3,000)] were applied and slides were incubated at 
4°C overnight in a humidified chamber before application of 
species-specific, Alexa Flour-488 or Alexa Flour-594 secondary 
antibodies (Invitrogen, Australia) for 1 h at room temperature. 
Finally, slides were washed and mounted in Fluorescence 
Mounting Medium (Dako, Australia). Images were captured 
on Olympus microscope and CellSense Live Science Imaging 
Software program (Olympus, Germany) used for counting the 
positive cells in the AD-like lesions of Flii+/−, wild-type, and FliiTg/Tg 
mice. Negative controls included replacing primary antibodies 
with normal rabbit IgG, or normal mouse IgG. For verification of 
staining, non-specific binding was determined by omitting pri-
mary or secondary antibodies. All control sections had negligible 
immunofluorescence.
rTq-Pcr
Harvested tissue was snap-frozen in liquid nitrogen and total 
RNA was isolated using Ultraclean Tissue and Cell RNA Isolation 
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Kit (MoBio Laboratories, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Total cDNA was synthesized using 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
CA, USA) according to manufacturer’s protocol. Quantitative 
PCR was performed using iQ SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA, USA) in triplicate reactions. The 
plates were placed in a CFX Connect Real-Time PCR Detection 
System (Bio-Rad Laboratories, Hercules, CA, USA). Reactions 
underwent 30 s at 95°C, then 40 cycles of 5 s at 95°C, 20 s at 60°C, 
and 10 s at 95°C before determination of melt curve between 65 
and 95°C. GAPDH and CyPA were used as reference genes and 
inter-reaction calculator method was applied for all plates. For 
relative comparison, the cycle threshold value (Ct) was analyzed 
using the ΔΔCt method and data reported as Ct normalized to 
reference genes. Sequences for PCR primers are listed in Table S1 
in Supplementary Material.
autoantibody immunofluorescence
In order to assess the degree of autoimmunity in OVA-induced 
AD-like skin of Flii+/−, wild-type, and FliiTg/Tg mice, sub-confluent 
primary wild-type mouse keratinocytes were stained with mouse 
sera of AD-induced mice following established protocols (13, 29). 
Briefly, primary keratinocytes were isolated from murine epi-
dermis as previously described (30), grown on glass coverslips 
and washed in 1× phosphate-buffered saline before paraformal-
dehyde (4%) fixation (10 min at room temperature). Fixed cells 
were subsequently permeabilized using 0.2% Triton-X-100 and 
0.5% BSA in 1× phosphate-buffered saline (5 min at room tem-
perature) before incubation with pooled murine serum (n = 3) 
diluted (1 in 10) in 0.5% BSA in 1× phosphate-buffered saline for 
1 h. Bound murine IgG was detected with Alexa Flour 633 goat 
anti-mouse IgG (1 in 1,000; #A21050; Invitrogen, Mulgrave, VIC, 
Australia) in 1× phosphate-buffered saline for 1 h at room tem-
perature. Following repeated 2 min washes with 1× phosphate-
buffered saline, cells were stained with DAPI nucleic acid stain 
(Sigma-Aldrich) for 5 min at room temperature before washing 
and mounting for imaging. Negative controls included omitting 
the incubation with mouse serum. All control sections had neg-
ligible immunofluorescence. Staining pattern of autoantibodies 
was assessed using the Olympus microscope and CellSense Live 
Science Imaging Software program (Olympus, Germany).
immunoblot analysis of aD serum 
autoreactive antibodies
Protein was extracted from WT murine keratinocytes using 
standard protein extraction protocols (31). Samples of extracted 
protein (20 µg) were run on 10% SDS-PAGE gels (30 min; 200V) 
and transferred to nitrocellulose by wet transfer (1  h; 100V). 
Membranes were cut into strips, blocked in 3% bovine serum 
albumin (Sigma) for 30  min, and probed with murine serum 
diluted (1 in 10) in tris-buffered saline containing 3% BSA and 
0.1% Tween overnight. After washing, horseradish peroxidase-
conjugated goat anti-murine immunoglobulin secondary anti-
body was added for a further 1 h at room temperature. Stringent 
washes were performed before detection of horseradish peroxi-
dase and exposure using GeneSnap analysis program (SynGene, 
Frederick, MD, USA).
statistical analysis
Statistical differences were determined using the Student’s t-test 
or one-way ANOVA. For data not following a normal distribu-
tion, the Mann–Whitney U test was performed. A P value of less 
than 0.05 was considered significant.
resUlTs
Flii-Deficient Mice exhibit reduced  
OVa-induced aD-like skin Disease
The repeated epicutaneous exposure of OVA (Figure  1A) on 
mouse skin results in an AD-like skin disease with histological 
and phenotypic features of human AD, including erythema, skin 
thickening, and a localized immune response (25). Flii homozy-
gous (Flii−/−) mice are embryonic lethal (26); therefore, using the 
OVA-induced AD-like skin mouse model, the severity of OVA-
induced AD-like lesions was determined in response to different 
Flii gene levels in Flii heterozygous (Flii+/−), normal (Flii+/+), and 
Flii transgenic (FliiTg/Tg) mice. All three mice genotypes developed 
localized inflammation which increased following each week 
of OVA exposure. Flii-deficient mice showed reduced levels of 
inflammation and scaling (Figure 1B). Spectrophotometric meas-
urement of the redness of the OVA exposed skin showed that Flii-
deficient mice had significantly less erythema (Figure 1B) than 
wild-type and FliiTg/Tg counterparts at day 50 of the experiment. 
Similarly, the degree of TEWL was also significantly reduced in 
Flii+/− mice and very similar to that observed in control animals 
(Figure 1C). Control mice administered saline only showed no 
evidence of AD-like inflammation macroscopically or any devel-
opment of erythema or TEWL (Figures 1B–D).
A hallmark of AD is skin thickening with a marked influx of 
leukocyte and mast cell inflammatory infiltrate. All OVA-induced 
AD-like skin sections showed evidence of AD compared to control 
saline exposed skin including a degree of epidermal hyperplasia 
and edema coupled with inflammatory lymphocytic and mast cell 
dermal infiltrate (Figures 2A–C). Examining the skin thickness 
in OVA-induced AD-like skin lesions revealed that deficient Flii 
mice had significantly thinner skin than OVA-induced AD-like 
skin lesions of wild-type and FliiTg/Tg mice (Figure 2A). Assessment 
of lymphocytic and mast cell dermal infiltrate showed that Flii 
deficiency consistently resulted in significantly decreased inflam-
matory cell numbers (Figures 2B,C). In contrast, both normal 
and increased Flii gene expression resulted in thickened epider-
mis, increased numbers of inflammatory cells (Figure 2B) and 
mast cells (Figure 2C). Control mice skin exposed to saline only 
gauze patch showed no evidence of AD-like dermatitis features 
microscopically and had low levels of inflammatory infiltrate in 
the dermis (Figures 2A–C).
anti-inflammatory cytokine mrna 
Profiles are increased in OVa-induced 
aD-like skin of Flii-Deficient Mice
OVA-induced AD-like skin lesions of Flii+/−, wild-type, and 
FliiTg/Tg mice were assessed for Flii and levels of cytokines and 
chemokines mediating the Th1 and Th2 inflammatory responses 
FigUre 2 | Mice with reduced Flii expression develop less severe OVA-induced atopic dermatitis (AD) skin-like lesions and tissue inflammation. (a) Representative 
images and graphical analysis of skin thickness in Flii+/−, WT, and FliiTg/Tg mice with OVA-induced AD skin-like lesions illustrating evidence of epidermal hyperplasia, 
edema, and lymphocytic infiltrate. Magnification 4× scale bar 200 µm. (B) Representative images and graphical analysis of lymphocytic inflammatory infiltrate in  
in Flii+/−, WT, and FliiTg/Tg mice with OVA-induced AD skin-like lesions illustrating decreased inflammation in Flii+/− mice skin. Magnification 1,000× scale bar 25 µm.  
(c) Representative images and graphical analysis of mast cells numbers in Flii+/−, WT, and FliiTg/Tg mice with OVA-induced AD skin-like lesions illustrating decreased 
inflammation in Flii+/− mice skin. Magnification 4× scale bar 200 µm. n = 8. Mean ± SEM. *<0.05.
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during AD pathogenesis. Flii-deficient mice showed approxi-
mately 25% decrease in Flii levels, while Flii over-expressing mice 
had a twofold increase in Flii levels compared to wild-type coun-
terparts (Figure 3). Flii gene levels were found to affect number 
of key cytokines and chemokines responsible for development 
of AD-like lesions. Notably, main Flii deficiency favored a Th1 
immune response and decreased inflammation with significant 
threefold increase in IFN-γ mRNA levels compared to FliiTg/Tg  
mice, decreased pro-inflammatory IL-4, and increased anti-
inflammatory IL-10 mRNA levels compared to both wild-type 
and FliiTg/Tg mice (Figure  3). Interestingly, Flii+/− OVA-induced 
AD-like skin lesions also showed increased IL-5 and IL-6 mRNA 
levels when compared to FliiTg/Tg mice but not wild-type coun-
terparts (Figure 3). In contrast, over-expression of Flii resulted 
in similar cytokine levels to wild-type counterparts, except sig-
nificantly increased TNF-α mRNA expression and significantly 
reduced IFN-γ mRNA expression when compared to both Flii-
deficient and wild-type mice, which would favor more severe AD 
manifestation. Cytokine mRNA levels of IL-13, IL-23, and IL-17A 
did not differ between OVA-induced AD-like skin lesions of three 
genotypes (Figure 3). Expression of CCL22 mRNA was signifi-
cantly increased in OVA-induced AD-like skin lesions of FliiTg/Tg 
mice compared to wild-type mice, while OVA-induced AD-like 
skin lesions of Flii+/− mice showed elevated CCL17 chemokine 
mRNA expression compared to FliiTg/Tg mice (Figure 4). CXCL9 
chemokine mRNA levels were found to be similar in all three 
genotypes (Figure 4). The unbalanced skewed ratio of Th1/Th2 
response in FliiTg/Tg mice was confirmed by immunohistochemi-
cal co-staining of T cell subset markers, namely Th1 (CD4 and 
T-bet), Th2 (CD4 and GATA-3), and Th17 (CD4 and ROR-γ) 
showing increased Th2 cell numbers in dermal area of FliiTg/Tg 
mice (Figures 5A–D).
FliiTg/Tg OVa-induced aD-like Disease 
Mice have altered autoreactivity Profiles 
compared With WT and Flii−/− Mice
To compare autoantibody formation in the OVA-induced 
AD-like disease model between Flii-deficient, wild-type, and 
Flii-overexpressing mice, serum samples collected at day 50 
FigUre 4 | Flii expression affects Th2 chemokine levels in OVA-induced atopic dermatitis (AD) skin-like lesions. mRNA levels of CCL17, CCL22, and CXCL9 
chemokines responsible for manifestation of AD were analyzed in the OVA-induced AD skin-like lesions of Flii+/−, wild-type, and FliiTg/Tg animals. OVA-induced AD 
skin-like lesions of Flii+/− mice have significantly higher levels of CCL17 compared to FliiTg/Tg counterparts, while CCL22 was significantly increased in OVA-induced 
AD skin-like lesions of FliiTg/Tg mice compared to wild-type controls. n = 6. Mean ± SEM. *<0.05.
FigUre 3 | OVA-induced atopic dermatitis (AD) skin-like lesions of Flii-deficient mice exhibit increased anti-inflammatory cytokine levels. mRNA levels of Flii, 
pro-inflammatory, and anti-inflammatory cytokines responsible for manifestation of AD were analyzed in the OVA-induced AD skin-like lesions of Flii+/−, wild-type,  
and FliiTg/Tg animals. OVA-induced AD skin-like lesions of Flii-deficient mice have significantly higher IFN-γ, reduced IL-4 signaling, and significantly higher levels of 
anti-inflammatory IL-10 while the Flii transgenic counterparts show significantly increased TNF-α and significantly reduced IFN-γ compared to wild-type animals. 
n = 6. Mean ± SEM. *<0.05.
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were assessed by immunofluorescence and immunoblot analy-
sis. Primary keratinocytes from wild-type mice were fixed and 
probed with pooled sera from experimental mice and staining 
patterns analyzed using fluorescence microscopy. Cytoplasmic 
and perinuclear staining within keratinocytes was apparent after 
incubation with sera from all three genotypes, however, only sera 
from OVA-induced AD-like disease FliiTg/Tg mice produced strong 
nuclear staining patterns (Figure 6A). To further elucidate auto-
reactivity in these samples, keratinocyte whole-cell lysates were 
separated via SDS-PAGE, transferred to nitrocellulose mem-
brane, and probed with pooled sera (Figure  6B). Additionally, 
autoreactivity patterns of individual mouse sera are shown in 
Figure S1 in Supplementary Material. Regions of differential 
autoreactivity were detected at 145, 70, 60, and 43 kDa band sizes 
(black arrows). Immunoblot analysis of sera (Figure  6C) from 
individual mice found that autoreactivity was highest in wild-type 
mice (50%) and FliiTg/Tg mice (43%), while Flii-deficient (Flii+/−) 
mice showed the lowest degree of autoreactivity (25%). Positive 
autoreactive bands at 70 kDa were also different in FliiTg/Tg mice 
compared to the two other genotypes, which may be responsible 
for the nuclear staining pattern observed in immunofluorescence 
analysis. Immunoblot analysis of sera from normal non-dermatitis 
mice from each genotype were also analyzed; no autoreactivity 
was detected (Figure S2 in Supplementary Material).
DiscUssiOn
Flii is a cytoskeletal protein with important roles in skin develop-
ment, tight junction function, skin barrier establishment, and 
recovery post injury which is upregulated in response to tissue 
FigUre 5 | Mice with increased Flii expression exhibit increased Th2 cell numbers within OVA-induced atopic dermatitis (AD) skin-like lesions. (a) Representative 
images and graphical analysis of Th1 (CD4+T-bet+) cell numbers in AD skin-like lesions within Flii+/−, WT, and FliiTg/Tg mice. (B) Representative images and graphical 
analysis of Th2 (CD4+GATA-3+) cell numbers in AD skin-like lesions within Flii+/−, WT, and FliiTg/Tg mice. (c) Representative images and graphical analysis of Th17 
(CD4+RORγ+) cell numbers in AD skin-like lesions within Flii+/−, WT, and FliiTg/Tg mice. (D) Ratio of Th1 to Th2 cells within AD skin-like lesions of Flii+/−, WT, and FliiTg/Tg 
mice. Magnification 4× scale bar 200 µm. n = 6. Mean ± SEM. *<0.05.
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inflammation and wounding (22, 31). The secreted form of Flii 
has been shown to affect innate immune signaling pathways and 
modulate cell activity and cytokine secretion from fibroblasts and 
macrophages in vitro (17, 20). Recent studies have described the 
contribution of Flii over-expression in exacerbation of inflam-
matory conditions, including psoriasiform dermatitis (24) and 
an autoimmune inflammation-mediated epidermolysis bullosa 
acquisita (23, 32).
To determine if Flii affects AD development and severity, mice 
with low (Flii+/−), normal (Flii+/+), and high (FliiTg/Tg) expression 
of the Flii gene were exposed to repeated epicutaneous exposure 
to OVA and induced to form AD-like skin lesions. In contrast 
to our original hypothesis, Flii over-expression did not result in 
a more exacerbated development of erythema and AD-like skin 
lesions. However, reduced Flii levels in Flii-deficient mice led to 
significantly decreased development of AD-like skin lesions as 
marked by decreased erythema, TEWL, epidermal hyperplasia, 
and lymphocytic and mast cell tissue infiltrate compared to both 
wild-type and FliiTg/Tg mice. Despite increased IFN-γ levels, the 
AD lesions of Flii+/− mice had reduced IL-4, which may contribute 
significantly to the reduced skin thickening in this model of AD 
(33). These findings are in agreement with studies which demon-
strated that reducing Flii expression, either genetically or using 
Flii neutralizing antibodies, decreased tissue inflammation, and 
disease severity in mouse models of psoriasiform dermatitis and 
epidermolysis bullosa acquisita (23, 24, 32).
Genetically modified mice engineered to over-express Th2 
cytokines develop skin barrier defects and AD spontaneously (34). 
The formation of AD lesions is known to be triggered by produc-
tion of Th2 cytokines by mast cells and CD4+ T cells which also 
promote IgE production by B cells, while Th1 cells secrete IFN-γ to 
suppress proliferation of Th2 cells and IgE synthesis (35, 36). The 
dominance of Th2 cytokines in AD cause decreased expression of 
fillagrin and other barrier promoting molecules found in the skin 
(3). Examining the levels of cytokines and chemokines produced 
in AD-like lesional skin of Flii+/−, wild-type, and FliiTg/Tg mice 
revealed decreased IFN-γ levels in FliiTg/Tg mice suggestive of Th2 
immune responses, while Flii+/− had increased IFN-γ levels and 
decreased clinical AD severity suggestive of potential Flii effect 
on IgE synthesis, however, this is yet to be investigated. Analysis 
of T-helper subsets within lesional skin showed a significantly 
Th2 skewed response in OVA-induced AD-like lesions of FliiTg/Tg  
mice with higher numbers of CD4+GATA3+ cells compared to 
AD-like lesions of Flii+/− or wild-type counterparts who showed 
significantly higher Th1:Th2 ratio. Additionally, AD-like lesions 
of FliiTg/Tg mice showed increased pro-inflammatory TNF-α 
cytokine levels and while TNF-α has been demonstrated to 
promote the AD development (37) we did not observe increased 
FigUre 6 | Over-expression of Flii produces an altered autoantibody profile in murine OVA-induced atopic dermatitis (AD) skin-like disease. (a) Representative 
images of IF microscopy staining patterns produced by mouse autoreactive IgG (red) and DAPI nuclear counterstaining (blue) in primary mouse keratinocytes. 
Magnification 20×; scale bar 50 µm. Antibodies from OVA-induced AD skin-like lesions of Flii+/− and WT mice producing a predominantly cytoplasmic (white arrow) 
and perinuclear (green arrow) staining patterns, while antibodies from OVA-induced AD skin-like lesions of FliiTg/Tg mice produce a strong cytoplasmic, perinuclear 
(green arrow), and nuclear (black arrow) staining patterns. (B) Western blot analysis of murine keratinocyte proteins probed with pooled sera from OVA-induced 
AD-like mice (2–3 mice per lane); black arrows represent regions of autoreactivity. (c) Autoreactivity summary of Western blot results from murine keratinocyte  
lysate probed with sera from individual mice.
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AD severity in these mice in this model of OVA-induced AD. 
As mast cell numbers were not significantly increased in FliiTg/Tg 
mice, and T-helper cells were heavily skewed toward a Th2 phe-
notype within FliiTg/Tg lesions, excess TNF-α was likely produced 
by other cell types such as macrophages, which is further sup-
ported by increased CCL22 chemokine levels observed in FliiTg/Tg  
mice. Interestingly, previous studies have shown that secreted 
Flii reduces macrophage secretion of TNF-α in vitro (20) while 
in vivo studies using a mouse model of psoriasiform dermatitis 
showed reduced TNF-α levels in response to reduced Flii (24) 
which was not observed in this model of OVA-induced AD. 
These findings may reflect inherent differences between in vivo 
and in vitro studies, for example differences in complex in vivo, 
multicellular environments, as well as differences in different 
models of inflammatory skin diseases.
In agreement with previous studies demonstrating decreased 
tissue inflammation and inflammatory cytokine secretion in 
Flii-deficient mice (24, 32), OVA-induced AD-like skin lesions of 
Flii+/− mice showed a reduced inflammatory response marked by 
significantly increased anti-inflammatory IL-10 secretion as well 
as significantly increased IFN-γ and significantly reduced IL-4 
levels. Indeed, IL-4 has been shown to be essential for eosinophil 
recruitment, Th2 cell differentiation, and IgE production (38). The 
increased CCL17 expression observed in AD lesions of Flii+/− mice 
compared to FliiTg/Tg mice may be a potential mechanism to 
restore Th1/Th2 balance, as CCL17 has previously been shown to 
induce a Th2-dominated inflammatory reaction (39). Reduction 
of Flii levels did not alter IL-23 and IL-17A cytokine levels as 
previously observed in psoriasiform dermatitis (24) suggesting 
that Th17 responses are not involved in this model of AD. Despite 
significant differences in IFN-γ levels between three genotypes, 
CXCL9 chemokine levels were not altered between genotypes 
in this model of AD. IL-13 levels were also not significantly dif-
ferent between three genotypes, however, there was a trend to 
higher levels in FliiTg/Tg mice OVA-induced AD-like skin lesions 
and IL-13 cytokine has previously been linked to autoantibody 
production in early rheumatoid arthritis (40).
Autoimmunity has been increasingly recognized to play part 
in exacerbating the severity of AD (6, 9, 12) as a consequence 
of both humoral and cellular and immunity (6). It is postulated 
that IFN-γ signaling during AD pathogenesis may promote the 
development of autoimmunity as IFN-γ overexpressing mice 
spontaneously develop autoantibodies (41, 42) and deletion of 
the IFN-γ receptor inhibits autoantibody production in lupus-
prone mice (43). On the basis of our findings showing altered 
AD severity and altered Th1/Th2 responses including significantly 
altered IFN-γ expression with different Flii genotypes, we exam-
ined the effect of Flii levels on autoimmunity in OVA-induced 
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AD-like skin lesions. The decreased severity of AD observed in 
Flii+/− mice also correlated with the reduced degree of autoreac-
tivity (50% reduction vs WT), and further studies are required 
to investigate whether the autoantibodies from OVA induced 
AD-like skin mice contribute to or are a product of the observed 
AD-like symptoms. Immunoblot analysis of sera from normal 
non-dermatitis mice showed no autoreactivity suggesting that 
autoantibody development was disease-specific. Interestingly, 
both Flii+/− and wild-type mice showed similar autoantibody 
staining patterns and regions of differential autoreactivity. FliiTg/Tg  
mice showed similar levels of autoreactivity compared to wild-
type mice, however, in addition to the cytoplasmic and perinuclear 
staining pattern observed in all genotypes, the sera of these mice 
had a strong nuclear staining pattern. This pattern may indicate 
the presence of disease-mediating antinuclear antibodies which 
have been clinically associated with AD and other inflammatory 
skin disorders (44–46). Flii has previously been shown to affect 
TLR signaling pathways, both intracellularly and extracellularly, 
hence modulating innate inflammatory responses and directly 
impacting immune signaling, however, the potential role of Flii 
in autoimmunity has not been explored to date. Further studies 
are required to determine if autoreactivity in Flii genetic mice is 
a direct result of the impact of Flii on immune signaling or if it 
is secondary to increased pathology observed in these animals. 
In addition, determining the subtype of autoreactive immuno-
globulins developed in the OVA-challenged murine model of AD 
would allow more comparison to be drawn to findings of previous 
clinical cohorts (10, 47).
While major differences between human AD and murine 
models have been demonstrated (47, 48), models of AD promote 
our understanding of the complex pathogenesis of human AD, 
and identify potential novel targets for design of targeted biolog-
ics (49). Here, we have demonstrated that Flii is a novel target in 
AD and that reducing its levels decreased the severity of AD in 
the ovalbumin-challenged murine model of AD. Additionally, we 
have examined the role of autoimmunity in this model of AD and 
while the exact mechanisms are yet to be identified, our results 
suggest that the effects of Flii upon Th1/Th2 balance and autoim-
munity are important during AD pathogenesis.
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